Ajax Strategies

Ajax Therapeutics is a biotechnology company focused on developing next-generation therapies for myeloproliferative neoplasms (MPNs) and other hematologic malignancies. The company utilizes a proprietary computational platform that integrates structure-based drug design with artificial intelligence to identify highly selective Type II JAK2 inhibitors. By targeting the inactive conformation of the JAK2 enzyme, Ajax aims to overcome the limitations of current Type I inhibitors, potentially offering disease-modifying benefits and improved safety profiles for patients with myelofibrosis and polycythemia vera. Headquartered in New York, the company was founded by world-renowned experts in hematology and computational chemistry to address significant unmet needs in blood cancers.